NLRP3 and rheumatoid arthritis: They suggest that NLRP3-induced IL-1β activation contributes to sustaining and shaping the inflammatory/immune processes in RA, thus, the NLRP3 inflammasome may be a suitable pharmacological target of RA treatment [147].